Egypt

The Egyptian Drug Authority (EDA) is the primary regulatory body responsible for overseeing the registration, quality control, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and related health products in Egypt. Established under Law No. 151 of 2019, which replaced the Egyptian Drug Authority's predecessor structures, the EDA operates under the auspices of the Ministry of Health and Population (MoHP). The general approval process requires applicants to submit a registration dossier for review, followed by technical evaluation, laboratory testing where applicable, and final approval before a product may be legally marketed or imported into the country.

Submissions to the EDA must generally follow the Common Technical Document (CTD) format, which has been progressively adopted to align Egypt with international standards. A local authorized representative or a registered Egyptian agent is mandatory for foreign manufacturers seeking product registration. Egypt has undertaken notable regulatory reforms in recent years, including the digitization of submission portals, streamlined fast-track pathways for innovative or priority health products, and increased alignment with the World Health Organization (WHO) prequalification standards. Recognition of approvals from stringent regulatory authorities (SRAs) such as the US FDA, EMA, and others may facilitate expedited review in certain product categories, and post-market surveillance obligations, including adverse event reporting, are enforced as a condition of continued registration.

Public procurement of health products in Egypt is primarily coordinated through the Ministry of Health and Population (MoHP) and its affiliated bodies, most notably the General Authority for Government Services (GAGS) and the Central Administration for Pharmaceutical Affairs (CAPA). Large-scale national tenders are organized centrally, with the Egyptian Health Affairs Organization (EHAO) playing a key role in procurement and distribution for the public sector. The Universal Health Insurance Authority (UHIA), established under Law No. 2 of 2018, is progressively expanding its purchasing role as Egypt rolls out its universal health coverage (UHC) scheme across governorates, which is expected to significantly consolidate and reshape public procurement volumes and criteria over the coming years.

The private sector represents a substantial and growing channel for health product distribution in Egypt, operating through a network of private hospitals, clinics, and retail pharmacies that procure independently from local importers and distributors. Donor-funded procurement also plays a meaningful role, particularly in infectious disease control programs, with organizations such as UNICEF, the Global Fund, USAID, and the World Bank supporting procurement for HIV, tuberculosis, hepatitis C, and maternal and child health initiatives. Egypt has an established and significant local pharmaceutical manufacturing base, and government policy actively encourages local production through preferential pricing in public tenders, reduced registration fees for locally manufactured products, and strategic partnerships under national industrial development frameworks, creating both opportunities and competitive considerations for foreign market entrants.